Acrizanib Uses, Dosage, Side Effects and more
Acrizanib is under investigation in clinical trial NCT02355028 (LHA510 Proof-of-concept Study as a Maintenance Therapy for Patients With Wet Age-related Macular Degeneration).
| Attribute | Details |
|---|---|
| Trade Name | Acrizanib |
| Generic | Acrizanib |
| Acrizanib Other Names | Acrizanib |
| Type | |
| Formula | C20H18F3N7O2 |
| Weight | Average: 445.406 Monoisotopic: 445.147407337 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
